MX2014002208A - Inhibidores de serina/treonina quinasa. - Google Patents

Inhibidores de serina/treonina quinasa.

Info

Publication number
MX2014002208A
MX2014002208A MX2014002208A MX2014002208A MX2014002208A MX 2014002208 A MX2014002208 A MX 2014002208A MX 2014002208 A MX2014002208 A MX 2014002208A MX 2014002208 A MX2014002208 A MX 2014002208A MX 2014002208 A MX2014002208 A MX 2014002208A
Authority
MX
Mexico
Prior art keywords
threonine
serine
pak1 inhibitors
pak1
inhibitors
Prior art date
Application number
MX2014002208A
Other languages
English (en)
Inventor
Wendy Lee
Ignacio Aliagas-Martin
James Crawford
Simon Mathieu
Joachim Rudolph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014002208A publication Critical patent/MX2014002208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que tienen la fórmula I en donde A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb y n son como se define aquí, son inhibidores de PAK1. También se describen composiciones y métodos para tratar cáncer y desórdenes hiperproliferativos.(ver Fórmula).
MX2014002208A 2011-08-25 2012-08-24 Inhibidores de serina/treonina quinasa. MX2014002208A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527453P 2011-08-25 2011-08-25
PCT/EP2012/066468 WO2013026914A1 (en) 2011-08-25 2012-08-24 Serine/threonine pak1 inhibitors

Publications (1)

Publication Number Publication Date
MX2014002208A true MX2014002208A (es) 2014-05-28

Family

ID=46799208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002208A MX2014002208A (es) 2011-08-25 2012-08-24 Inhibidores de serina/treonina quinasa.

Country Status (11)

Country Link
US (1) US8637537B2 (es)
EP (1) EP2748159A1 (es)
JP (1) JP2014524456A (es)
KR (1) KR20140062079A (es)
CN (1) CN104024248A (es)
BR (1) BR112014003997A2 (es)
CA (1) CA2844729A1 (es)
HK (1) HK1197232A1 (es)
MX (1) MX2014002208A (es)
RU (1) RU2014109897A (es)
WO (1) WO2013026914A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011126903A2 (en) 2010-03-30 2011-10-13 Verseon, Inc. Multisubstituted aromatic compounds as inhibitors of thrombin
KR102091894B1 (ko) * 2012-05-03 2020-03-20 제넨테크, 인크. Lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
CN103724276A (zh) * 2013-12-13 2014-04-16 成都丽璟科技有限公司 一种由硝基苯胺制备苯并咪唑类化合物的新方法
WO2016025641A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and an egfr inhibitor and related methods
HRP20221287T1 (hr) * 2015-02-27 2023-02-03 Verseon International Corporation Supstituirani pirazolni spojevi kao inhibitori serin proteaze
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
CN109311874B (zh) 2016-04-20 2021-07-30 百时美施贵宝公司 经取代的二环杂环化合物
WO2017205425A1 (en) * 2016-05-24 2017-11-30 President And Fellows Of Harvard College Compounds for organic light emitting diode materials
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
EP3601267A1 (en) 2017-03-21 2020-02-05 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
CN108689901B (zh) * 2018-05-05 2020-04-28 西北大学 一种氮杂环丙烯类化合物的合成方法
JPWO2020017569A1 (ja) 2018-07-17 2021-12-02 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
US20220226299A1 (en) 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
CN116368125A (zh) * 2020-10-30 2023-06-30 第一三共株式会社 3-甲基-4-卤代-吲哚衍生物的制造方法
WO2023164612A1 (en) * 2022-02-25 2023-08-31 Nalo Therapeutics Modulators of myc family proto-oncogene protein

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1318997B1 (en) 2000-09-15 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6653300B2 (en) 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0128134D0 (en) 2001-11-23 2002-01-16 Syngenta Participations Ag A product for use in agriculture or horticulture
US20050113398A1 (en) 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CN101208093A (zh) 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
MX2007014328A (es) * 2005-05-16 2008-02-12 Astrazeneca Ab Compuestos quimicos.
DK1945631T3 (da) * 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
AR056764A1 (es) 2005-11-03 2007-10-24 Vertex Pharma Aminopirimidinas utiles como inhibidores de quinasa
CN101360740A (zh) 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
MX2009011810A (es) 2007-05-02 2010-01-14 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
CN101687852A (zh) 2007-05-24 2010-03-31 沃泰克斯药物股份有限公司 可用作激酶抑制剂的噻唑类和吡唑类化合物
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
MY160820A (en) * 2009-11-13 2017-03-31 Genosco Kinase inhibitors
CN104011050A (zh) * 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物

Also Published As

Publication number Publication date
HK1197232A1 (en) 2015-01-09
RU2014109897A (ru) 2015-09-27
CA2844729A1 (en) 2013-02-28
BR112014003997A2 (pt) 2017-03-21
US8637537B2 (en) 2014-01-28
WO2013026914A1 (en) 2013-02-28
EP2748159A1 (en) 2014-07-02
JP2014524456A (ja) 2014-09-22
CN104024248A (zh) 2014-09-03
US20130225620A1 (en) 2013-08-29
KR20140062079A (ko) 2014-05-22

Similar Documents

Publication Publication Date Title
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
PH12014501365A1 (en) Compounds
MX339873B (es) Inhibidores de serina/treonina cinasa.
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MX2015001720A (es) Hetero-azepinonas sustituidas.
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
PH12015501038A1 (en) Inhibitors of iap
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
MY169267A (en) New aryl-quinoline derivatives
PH12016501071A1 (en) Serine/threonine kinase inhibitors
MX2012008141A (es) Compuestos y metodos.
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
PH12015500399A1 (en) Azaindolines
IN2015DN02588A (es)
MX2012005155A (es) Compuestos de quinazolina.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.